<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02544204</url>
  </required_header>
  <id_info>
    <org_study_id>JTCS-007</org_study_id>
    <nct_id>NCT02544204</nct_id>
  </id_info>
  <brief_title>SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease</brief_title>
  <acronym>STOP-PAD</acronym>
  <official_title>A Phase 2B Randomized Double Blind Placebo Controlled Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Direct Intramuscular Injection as Adjunct to Revascularization of Infrapopliteal Lesions in Subjects With Advanced Peripheral Artery Disease and Tissue Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juventas Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Juventas Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy of the administration of JVS-100 delivered via direct
      intramuscular injections on a 3 month and 6 month composite endpoint of wound progression,
      healing and limb loss in patients with severe peripheral arterial disease with non-healing
      chronic wounds who undergo an open bypass grafting or endovascular procedure for treatment of
      infrapopliteal disease and are dosed within 12 days and 3 months following the procedure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The composite is designed to quantify clinically significant improvement or worsening over baseline by assigning a score to each patient that represents their overall outcome.</measure>
    <time_frame>3 months</time_frame>
    <description>Change from baseline in the composite endpoint at 3 months in all treated (or one JVS-100 dose group) compared to all placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The composite is designed to quantify clinically significant improvement or worsening over baseline by assigning a score to each patient that represents their overall outcome.</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline in the composite endpoint at 6 months in all treated (or one JVS-100 dose group) compared to all placebo.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>8 mg JVS-100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biological/Vaccine: JVS-100 Injection Intramuscular Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 mg placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Biological/Vaccine: Placebo Injection Intramuscular Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>16 mg JVS-100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biological/Vaccine: JVS-100 Injection Intramuscular Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>16 mg placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Biological/Vaccine: Placebo Injection Intramuscular Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JVS-100</intervention_name>
    <description>Biological/Vaccine: JVS-100 Intramuscular Injection</description>
    <arm_group_label>8 mg JVS-100</arm_group_label>
    <arm_group_label>16 mg JVS-100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Biological/Vaccine: Placebo Intramuscular Injection</description>
    <arm_group_label>8 mg placebo</arm_group_label>
    <arm_group_label>16 mg placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          -  Age ≥18

          -  Currently receiving standard of care wound treatment (&gt;2 weeks) for chronic wounds or
             gangrene including as indicated: debridement, pressure offloading, infection control,
             and/or maintenance of a moist wound environment.

          -  Diagnosis of advanced PAD with tissue loss (ulceration and/or dry gangrene) on the
             foot of the index leg with an ulcer size of at least 0.5 cm2 and &lt;25 cm2. Index wounds
             on the heel must be &lt;10 cm2 that cannot be probed to bone, have exposed bone or
             osteomyelitis.

          -  Post revascularization intervention inclusion criteria include an attempt at open
             bypass grafting or endovascular intervention of a popliteal/infrapopliteal lesion(s)
             on the same leg that has tissue loss without significant improvement in TBI post
             intervention. The following will be accepted as demonstrating a lack of post
             intervention toe brachial index (TBI) improvement:

               -  TBI ≤ 0.51or;

               -  Toe pressure ≤50 mmHg with flat or dampened wave forms or;

               -  Skin Perfusion pressure ≤40 mmHg at mid foot level or;

               -  TcPO2 ≤40 mmHg

          -  Subjects willing to forgo treatment with hyperbaric oxygen, nerve stimulation or
             sympathectomy for the treatment of advanced PAD from time of consent to 6 months
             following the initial injection of study drug

        Major Exclusion Criteria:

          -  Previous major amputation of the leg to be treated or planned major amputation or
             transmetatarsal amputation within the first month following enrollment.

          -  Only a short segment superficial femoral artery lesion - consistent with Inter-Society
             Consensus for the Management of Peripheral Arterial Disease (TASC II) A or B category,
             and no infrapopliteal disease

          -  Staged or planned intervention in the index leg within 30 days after the index
             procedure

          -  Acute limb-threatening ischemia, trauma, known non-atherosclerotic vascular disease

          -  Non-salvageable limb defined as major tissue loss and an unsalvageable foot;

          -  Wounds that have decreased in size by &gt;50% between the Screening visit and Day 0.

          -  If patient has active infection of the index limb that is being treated, and, in the
             opinion of treating physician, will not lead to an amputation within the next 3
             months, the patient can be enrolled.

          -  Inability to safely perform a revascularization procedure due to uncontrolled diabetes
             or other medical condition.

          -  Presence of any other condition that, in the opinion of the investigator, might
             compromise any aspect of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardiovascular Associates of the Southeast</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chris Huff, MD</last_name>
      <phone>205-795-5193</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Davis</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Laird, MD</last_name>
      <phone>916-734-4156</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Heart Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Henry, MD</last_name>
      <phone>310-423-1231</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown UH</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Kim, MD</last_name>
      <phone>202-444-0793</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hosptial - Baycare</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Les Miller, MD</last_name>
      <phone>727-489-2543</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nirat Beohar, MD</last_name>
      <phone>305-674-2121</phone>
      <phone_ext>56022</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sai Sadanandan, MD</last_name>
      <phone>813-875-9000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Ho, MD</last_name>
      <phone>513-585-1777</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>RUMC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Snell, MD</last_name>
      <phone>312-942-8707</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Walker, MD</last_name>
      <phone>985-873-5613</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. John Hospital and Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Davis, MD</last_name>
      <phone>313-343-4714</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Misra, MD</last_name>
      <phone>507-538-6419</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates Research</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Murray Estess, MD</last_name>
      <phone>662-377-5447</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Luke's Mid America Heart Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matt Bunte, MD</last_name>
      <phone>816-932-4948</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Runback, MD</last_name>
      <phone>201-530-7968</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UNC</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Marston, MD</last_name>
      <phone>919-843-1268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NC Heart and Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matt Hook, MD</last_name>
      <phone>919-740-4897</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Summa Health</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Dunn, MD</last_name>
      <phone>330-253-8195</phone>
      <phone_ext>4259</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehdi Shishehbor, DO</last_name>
      <phone>216-444-0922</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Metro Health</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Gandhi, MD</last_name>
      <phone>216-778-2714</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikram Kashyap, MD</last_name>
      <phone>216-983-4719</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lifespan Health System</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Soukas, MD</last_name>
      <phone>401-793-4105</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>VCU</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Guzman, MD</last_name>
      <phone>804-628-2452</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwauke</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Gossett, MD</last_name>
      <phone>414-955-6749</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

